2020 Marker Analysis of Euro Breast Cancer, Clinical Trials, Therapeutics and Research
Summit

Gery Rifano

Market Analysis - Journal of Cell Science and Mutations (2021) Volume 5, Issue 1

2020 Marker Analysis of Euro Breast Cancer, Clinical Trials, Therapeutics and Research Summit

Gery Rifano^*

Surgery Resident, Department of Oncology, Kariadi General Hospital, Indonesia

*Corresponding Author:: Gery Rifano,
Surgery Resident, Department of Oncology, Kariadi General Hospital, Indonesia
E-mail: geryrifano@gmail.com

Copyrights: © 2021 The Authors. This is an open access article under the terms of the Creative Commons Attribution NonCommercial ShareAlike 4.0 (https://creativecommons.org/licenses/by-nc-sa/4.0/) Surgery Resident, Department of Oncology, Kariadi General Hospital, Indonesia.

Visit for more related articles at Journal of Cell Science and Mutations

Abstract

Breast cancer is the most commonly occurring cancer in women accounting for 46,000 new cases in 2005. In 2003 there were an estimated 172,000 women living in the UK with a history of breast cancer. The rates have been steadily increasing over the past 10?15 years but they may now be stabilizing. Only a small number of cases, less than 1% of the total, occur in men. The numbers of cases of breast cancer are highest in the screened age group, 50 to 69 years, but the rates are highest in those aged over 85 years. It is estimated that 5% of women have metastases at diagnosis and a further 35% will develop them over the following 10 years. There is little geographical variation in the incidence rates across the country but rates are highest in those in higher socioeconomic groups. The incidence in the UK is higher than other countries; in particularly those in Eastern Europe and the risk of developing breast cancer appear to increase in those who move from a lower incidence country to the UK.

Breast cancer is the most commonly occurring cancer in women accounting for 46,000 new cases in 2005. In 2003 there were an estimated 172,000 women living in the UK with a history of breast cancer.

The rates have been steadily increasing over the past 10–15 years but they may now be stabilizing. Only a small number of cases, less than 1% of the total, occur in men. The numbers of cases of breast cancer are highest in the screened age group, 50 to 69 years, but the rates are highest in those aged over 85 years. It is estimated that 5% of women have metastases at diagnosis and a further 35% will develop them over the following 10 years. There is little geographical variation in the incidence rates across the country but rates are highest in those in higher socioeconomic groups. The incidence in the UK is higher than other countries; in particularly those in Eastern Europe and the risk of developing breast cancer appear to increase in those who move from a lower incidence country to the UK.

Europe Cancer Market - Growth, Trends, and Forecast (2019-2024)

The driving factors for the progression of the European cancer therapeutics market include the ease in regulatory approval for novel cancer therapy in Europe, increase in healthcare spending for cancer, rising frequency of cancer, and strong R&D initiatives from key players.

The growing cancer among the population characterizes the second most important cause of death and disease in Europe, accounting for 1.9 million deaths every year. According to WHO, Europe encompasses only one-eighth of the total world population, but has nearby one-quarter of the total global cancer cases. About 3.7 million new patients are being reported every year in Europe. There are also other factors accredited to the rising frequency of cancer in Europe, i.e. unusual lifestyles and unfortunate diet, obesity, and lack of physical activity. Thus, the rising incidence and frequency of cancer is likely to drive the growth of the cancer therapeutics market in Europe during the forecast period.